IN THE CLAIMS

Please amend the claims as follows:

1. (amended) A composition comprising glycoprotein wherein at least one glycoprotein is a glycoprotein having at least one immunoglobulin CH2 domain containing N-linked G2 and G-2 oligosaccharide and the composition is substantially free of the glycoprotein [having at least one CH2 domain and] having an N-linked G1, G0, or G-1 oligosaccharide in the [its] CH2 domain.

2. (amended) The composition of claim 1 wherein the N-linked G2 or G-2 oligosaccharide further comprises a bisecting N-acetylglucoseamine [an antibody glycoprotein].

3. (amended) The composition of claim 2 wherein the [antibody] glycoprotein is a monoclonal antibody.

REMARKS

The Office has required restriction under 35 U.S.C. § 121 to one of the following inventions:

> Group I. Claims 1-20, drawn to a pharmaceutical composition comprising glycoprotein and an article of manufacture, classified in class 514, subclass 885.
> Group II. Claims 21-30, drawn to a method of producing the glycoprotein composition, classified in class 435, subclass 68.1.
> Group III. Claims 31-34, drawn to a method of treatment of a disease state, classified in class 424, subclass 133.1. (Paper 4, page 2)

The Office has alleged that groups I, II and III are three distinct inventions. (Paper 4, page 2). The Office has additionally required election of a specific glycoprotein composition selected from the following group for examination.

A) Anti-CD20 specific monoclonal antibody